JP2011521968A - プリンｐｉ３ｋ阻害剤化合物および使用方法 - Google Patents

プリンｐｉ３ｋ阻害剤化合物および使用方法 Download PDF

Info

Publication number
JP2011521968A
JP2011521968A JP2011511842A JP2011511842A JP2011521968A JP 2011521968 A JP2011521968 A JP 2011521968A JP 2011511842 A JP2011511842 A JP 2011511842A JP 2011511842 A JP2011511842 A JP 2011511842A JP 2011521968 A JP2011521968 A JP 2011521968A
Authority
JP
Japan
Prior art keywords
purin
morpholino
cancer
alkylene
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011511842A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011521968A5 (enExample
Inventor
ジョーゼット カスタネド，
イリーナ チャコーリー，
エイドリアン フォルクス，
ダニエル ピー． サザーリン，
ナン チ ワン，
Original Assignee
ジェネンテック， インコーポレイテッド
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェネンテック， インコーポレイテッド, エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2011521968A publication Critical patent/JP2011521968A/ja
Publication of JP2011521968A5 publication Critical patent/JP2011521968A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011511842A 2008-05-30 2009-05-29 プリンｐｉ３ｋ阻害剤化合物および使用方法 Pending JP2011521968A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5755908P 2008-05-30 2008-05-30
US61/057,559 2008-05-30
PCT/US2009/045603 WO2009146406A1 (en) 2008-05-30 2009-05-29 Purine pi3k inhibitor compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2011521968A true JP2011521968A (ja) 2011-07-28
JP2011521968A5 JP2011521968A5 (enExample) 2012-07-12

Family

ID=41017038

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011511842A Pending JP2011521968A (ja) 2008-05-30 2009-05-29 プリンｐｉ３ｋ阻害剤化合物および使用方法

Country Status (14)

Country Link
US (2) US8158624B2 (enExample)
EP (1) EP2279188B1 (enExample)
JP (1) JP2011521968A (enExample)
KR (1) KR20110042153A (enExample)
CN (1) CN102105474B (enExample)
AU (1) AU2009251291B2 (enExample)
BR (1) BRPI0909614A2 (enExample)
CA (1) CA2721851A1 (enExample)
ES (1) ES2533788T3 (enExample)
IL (1) IL208838A0 (enExample)
MX (1) MX2010012583A (enExample)
RU (1) RU2509081C2 (enExample)
WO (1) WO2009146406A1 (enExample)
ZA (1) ZA201007524B (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
JP2014530903A (ja) * 2011-10-28 2014-11-20 ノバルティスアーゲー 新規プリン誘導体および疾患の処置におけるその使用
JP2016517872A (ja) * 2013-05-02 2016-06-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２受容体アゴニストとしてのプリン誘導体
JP2018510192A (ja) * 2015-04-02 2018-04-12 セロン ファーマ エス．アー．Ｃｅｌｏｎ Ｐｈａｒｍａ Ｓ．Ａ． 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体
JP2018521111A (ja) * 2015-04-21 2018-08-02 ▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司Ｇｕｉｚｈｏｕ Ｂａｉｌｉｎｇ Ｅｎｔｅｒｐｒｉｓｅ Ｇｒｏｕｐ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． プリニル−ｎ−ヒドロキシルピリミジンホルムアミド誘導体、並びにその調製方法および使用
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5479346B2 (ja) 2007-10-05 2014-04-23 ベラステム・インコーポレーテッド ピリミジン置換プリン誘導体
CA2701292C (en) * 2007-10-25 2015-03-24 Genentech, Inc. Process for making thienopyrimidine compounds
GB0721095D0 (en) * 2007-10-26 2007-12-05 Piramed Ltd Pharmaceutical compounds
EP2215090B1 (en) * 2007-10-26 2015-03-04 F. Hoffmann-La Roche AG Purine derivatives useful as pi3 kinase inhibitors
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
CN101965335B (zh) 2008-01-04 2015-01-14 英特利凯恩有限责任公司 某些化学实体、组合物和方法
EP2346508B1 (en) 2008-09-26 2016-08-24 Intellikine, LLC Heterocyclic kinase inhibitors
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
CA2757485C (en) 2009-04-03 2017-01-17 Dizhong Chen Pyrimidine substituted purine compounds as kinase (s) inhibitors
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
KR20130026364A (ko) * 2009-05-27 2013-03-13 제넨테크, 인크. Ｐ110 델타에 대해 선택적인 비시클릭 피리미딘 ｐｉ3ｋ 억제제 화합물 및 사용 방법
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
CA2778686C (en) * 2009-11-12 2015-07-21 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
EP2499143B1 (en) * 2009-11-12 2016-03-16 F.Hoffmann-La Roche Ag N7-substituted purine and pyrazolopyrimidine compounds, compositions and methods of use
ES2593256T3 (es) 2010-05-21 2016-12-07 Infinity Pharmaceuticals, Inc. Compuestos químicos, composiciones y métodos para las modulaciones de cinasas
CA2802808A1 (en) * 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use
WO2012037226A1 (en) * 2010-09-14 2012-03-22 Exelixis, Inc. Inhibitors of pi3k-delta and methods of their use and manufacture
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
HRP20150127T1 (xx) * 2010-12-16 2015-03-13 F. Hoffmann - La Roche Ag Tricikliäśki spojevi pi3k-inhibitora i postupci njihove uporabe
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
HK1198475A1 (en) 2011-07-19 2015-05-08 无限药品股份有限公司 Heterocyclic compounds and uses thereof
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013015833A2 (en) * 2011-07-28 2013-01-31 Genentech, Inc Pik3ca h1047r knock-in non-human animal breast cancer model
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013090725A1 (en) * 2011-12-15 2013-06-20 Philadelphia Health & Education Corporation NOVEL PI3K p110 INHIBITORS AND METHODS OF USE THEREOF
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160027218A (ko) 2012-05-23 2016-03-09 에프. 호프만-라 로슈 아게 내배엽 및 간세포를 수득하고 사용하는 조성물 및 방법
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014068070A1 (en) 2012-10-31 2014-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
LT2914296T (lt) 2012-11-01 2018-09-25 Infinity Pharmaceuticals, Inc. Vėžio gydymas, panaudojant p13 kinazės izoformos moduliatorius
CN103936742B (zh) * 2013-01-17 2017-05-03 程鹏 含嘌呤基的新型pi3k抑制剂及其制备方法和应用
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PH12016500582B1 (en) 2013-10-04 2023-06-30 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
KR101982912B1 (ko) * 2013-10-16 2019-09-10 상하이 잉리 파마슈티컬 컴퍼니 리미티드 융합된 헤테로사이클릭 화합물, 이의 제조 방법, 약학적 조성물, 및 그 용도
CN103804380B (zh) * 2014-01-24 2016-05-18 温州医科大学 以IKK-β为靶点的2-氨基-8-取代鸟嘌呤衍生物、应用及其制备方法
JP6701088B2 (ja) 2014-03-19 2020-05-27 インフィニティー ファーマシューティカルズ， インコーポレイテッド Ｐｉ３ｋ−ガンマ媒介障害の治療で使用するための複素環式化合物
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015188369A1 (en) * 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Purine inhibitors of human phosphatidylinositol 3-kinase delta
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2016097949A1 (en) * 2014-12-17 2016-06-23 Pfizer Inc. Formulations of a pi3k/mtor-inhibitor for intravenous administration
HRP20190998T1 (hr) 2015-03-30 2019-10-18 Daiichi Sankyo Company, Limited 6-morfolinil-2-pirazolil-9h-purinski derivati i njihova primjena kao p13k inhibitora
WO2016205334A1 (en) 2015-06-16 2016-12-22 Vascular Strategies Llc Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
AU2016322552B2 (en) 2015-09-14 2021-03-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
BR112018077021A2 (pt) 2016-06-24 2019-04-02 Infinity Pharmaceuticals, Inc. terapias de combinação
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
WO2018062382A1 (ja) * 2016-09-29 2018-04-05 第一三共株式会社 ［２－（１－メチル－１ｈ－ピラゾール－４－イル）－６－（モルホリン－４－イル）－９ｈ－プリン－８－イル］［４－（モルホリン－４－イル）ピペリジン－１－イル］メタノン及びその製薬上許容される塩の結晶
ES2911522T3 (es) 2016-12-02 2022-05-19 Daiichi Sankyo Co Ltd Novedosa endo-ß-n-acetilglucosaminidasa
CA3114260A1 (en) * 2018-09-27 2020-04-02 Shanghai Yingli Pharmaceutical Co., Ltd Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof
CN111875606B (zh) * 2020-07-20 2023-04-07 武汉工程大学 一种基于虚拟对接获得的嘌呤类化合物及其制备方法和应用
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
CN116425751B (zh) * 2022-12-19 2024-01-23 艾立康药业股份有限公司 作为mat2a抑制剂的多环类化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522209A (ja) * 2007-03-21 2010-07-01 ワイス エルエルシー ＰＩ３キナーゼおよびｍＴＯＲの阻害剤としてのイミダゾロピリミジン類似体およびその使用
JP2011500775A (ja) * 2007-10-26 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3016378A (en) 1959-07-01 1962-01-09 Thomae Gmbh Dr K Amino-substituted purine derivatives
JPS60260579A (ja) 1984-01-13 1985-12-23 Yoshitomi Pharmaceut Ind Ltd プリン誘導体
DE3406533A1 (de) 1984-02-23 1985-08-29 Boehringer Mannheim Gmbh, 6800 Mannheim Verwendung von adenosin-derivaten als antiallergica und arzneimittel, die diese enthalten
US5332744A (en) 1989-05-30 1994-07-26 Merck & Co., Inc. Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
US5866702A (en) 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
US6790958B2 (en) * 1996-08-02 2004-09-14 Robert T. Lum Purine inhibitors of cyclin dependent kinase 2 & IKBA
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
JP2003146987A (ja) * 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
ES2360933T3 (es) 2000-04-27 2011-06-10 Astellas Pharma Inc. Derivados de heteroarilo condensados.
AU2002323475B2 (en) 2001-09-13 2006-09-28 Synta Pharmaceuticals Corp 2-aroylimidazole compounds for treating cancer
CA2463563A1 (en) 2001-10-12 2003-04-17 Irm Llc Kinase inhibitor scaffolds and methods for their preparation
US6949644B2 (en) 2001-10-12 2005-09-27 Irm Llc Methods for the synthesis of substituted purines
ATE355291T1 (de) * 2001-12-18 2006-03-15 Cv Therapeutics Inc A2a adenosinrezeptorantagonisten
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
US20050288503A1 (en) * 2002-09-06 2005-12-29 Adams Jerry L Novel compounds
CA2502356A1 (en) 2002-10-15 2004-04-29 Synta Pharmaceuticals Corp. Aromatic bicyclic heterocyles to modulate 1l - 12 production
WO2005000404A2 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB2431156A (en) * 2005-10-11 2007-04-18 Piramed Ltd 1-cyclyl-3-substituted- -benzenes and -azines as inhibitors of phosphatidylinositol 3-kinase
MX2008013583A (es) * 2006-04-26 2008-10-31 Genentech Inc Compuestos del inhibidor de fosfoinositido 3-cinasa y composiciones farmaceuticas que los contienen.
TW200831104A (en) 2006-10-04 2008-08-01 Pharmacopeia Inc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
BRPI0808746B8 (pt) * 2007-03-28 2021-05-25 Neurosearch As derivado de purinila como modulador do canal de potássio, composição farmacêutica, e, uso de um derivado de purinila.
US8362024B2 (en) * 2007-03-28 2013-01-29 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
TWI378933B (en) * 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CA2757485C (en) * 2009-04-03 2017-01-17 Dizhong Chen Pyrimidine substituted purine compounds as kinase (s) inhibitors
US8158625B2 (en) * 2009-05-27 2012-04-17 Genentech, Inc. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
KR20130026364A (ko) * 2009-05-27 2013-03-13 제넨테크, 인크. Ｐ110 델타에 대해 선택적인 비시클릭 피리미딘 ｐｉ3ｋ 억제제 화합물 및 사용 방법
CA2778686C (en) * 2009-11-12 2015-07-21 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
CA2802808A1 (en) * 2010-07-14 2012-01-19 F. Hoffmann-La Roche Ag Purine compounds selective for pi3k p110 delta, and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010522209A (ja) * 2007-03-21 2010-07-01 ワイス エルエルシー ＰＩ３キナーゼおよびｍＴＯＲの阻害剤としてのイミダゾロピリミジン類似体およびその使用
JP2011500775A (ja) * 2007-10-26 2011-01-06 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤として有用なプリン誘導体

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530903A (ja) * 2011-10-28 2014-11-20 ノバルティスアーゲー 新規プリン誘導体および疾患の処置におけるその使用
JP2016517872A (ja) * 2013-05-02 2016-06-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｂ２受容体アゴニストとしてのプリン誘導体
WO2014185367A1 (ja) * 2013-05-13 2014-11-20 第一三共株式会社 モルホリノプリン誘導体の製造方法
JP2018510192A (ja) * 2015-04-02 2018-04-12 セロン ファーマ エス．アー．Ｃｅｌｏｎ Ｐｈａｒｍａ Ｓ．Ａ． 免疫もしくは炎症性の疾患またはがんの処置に有用な７−（モルホリン−４−イル）ピラゾール［１，５−ａ］ピリミジン誘導体
JP2018521111A (ja) * 2015-04-21 2018-08-02 ▲貴▼州百▲霊▼企▲業▼集▲団▼制▲薬▼股▲分▼有限公司Ｇｕｉｚｈｏｕ Ｂａｉｌｉｎｇ Ｅｎｔｅｒｐｒｉｓｅ Ｇｒｏｕｐ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． プリニル−ｎ−ヒドロキシルピリミジンホルムアミド誘導体、並びにその調製方法および使用
JP2022552185A (ja) * 2019-10-09 2022-12-15 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤
JP7630502B2 (ja) 2019-10-09 2025-02-17 バイオクリスト ファーマスーティカルズ，インコーポレイテッド 経口補体因子ｄ阻害剤

Also Published As

Publication number Publication date
RU2010154428A (ru) 2012-07-10
CN102105474B (zh) 2014-01-08
BRPI0909614A2 (pt) 2015-09-22
MX2010012583A (es) 2011-02-24
US20090318411A1 (en) 2009-12-24
ES2533788T3 (es) 2015-04-14
KR20110042153A (ko) 2011-04-25
US8445487B2 (en) 2013-05-21
US20120135988A1 (en) 2012-05-31
IL208838A0 (en) 2011-01-31
CA2721851A1 (en) 2009-12-03
EP2279188B1 (en) 2015-01-28
EP2279188A1 (en) 2011-02-02
US8158624B2 (en) 2012-04-17
ZA201007524B (en) 2012-01-25
CN102105474A (zh) 2011-06-22
AU2009251291A1 (en) 2009-12-03
RU2509081C2 (ru) 2014-03-10
AU2009251291B2 (en) 2013-05-02
WO2009146406A1 (en) 2009-12-03

Similar Documents

Publication Publication Date Title
US8445487B2 (en) Purine PI3K inhibitor compounds and methods of use
JP5608099B2 (ja) ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP5736171B2 (ja) チアゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
JP5775171B2 (ja) 三環系ｐｉ３ｋ阻害剤化合物及びその使用方法
JP5689069B2 (ja) ピラゾロピリジンｐｉ３ｋ阻害剤化合物及び使用方法
JP6022691B2 (ja) ジオキシノ−及びオキサジン−［２，３−ｄ］ピリミジンｐｉ３ｋ阻害剤化合物及び使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131128

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140527